Bevespi Aerosphere generic
Bevespi Aerosphere is an aerosol medication for chronic obstructive pulmonary disease (COPD) owned by Astrazeneca. It contains the active ingredients Formoterol Fumarate and Glycopyrrolate, and was first approved for market use on April 25, 2016.
When will Bevespi Aerosphere generic be available?
Generics for Bevespi Aerosphere may become available after March 17, 2031. This release date is determined by the patent held by Astrazeneca, which is set to expire on this date.
Bevespi Aerosphere uses
Bevespi Aerosphere is used for the maintenance treatment of patients with COPD. The active ingredients Formoterol Fumarate and Glycopyrrolate work synergistically to relax the muscles in the airways, improving breathing in individuals suffering from this chronic respiratory condition.
Bevespi Aerosphere patent expiration
Bevespi Aerosphere is protected by a collection of patents, with titles ranging from compositions and delivery methods to detailed systems for respiratory delivery. It holds seven patents in total. The last patent, titled 'Compositions, methods and systems for respiratory delivery of two or more active agents,' is set to expire on March 17, 2031. Below are the details of the patent: